The Alliance for Continuing Education in the Health Professions annual conference in January included a session on on risk evaluation and mitigation strategy, or REMS, for long-acting and extended-release opioids. Now required by the Food and Drug Administration, these are of high interest to many CME providers (78 percent of those in the audience intended to do REMS education) and many of these would like to also use commercial support to do REMS (50 percent said they plan to apply for ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock thePrinter-friendly, you'll also gain access to exclusive premium content.

Already registered? here.